SBIO.L vs. ^GSPC

Last updated Apr 2, 2026

Compare and contrast key facts about Invesco Nasdaq Biotech UCITS ETF (SBIO.L) and S&P 500 Index (^GSPC).

SBIO.L is a passively managed fund by Invesco that tracks the performance of the NASDAQ Biotechnology TR USD. It was launched on Nov 6, 2014.

Performance

SBIO.L vs. ^GSPC - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Invesco Nasdaq Biotech UCITS ETF (SBIO.L) and S&P 500 Index (^GSPC). The values are adjusted to include any dividend payments, if applicable.

SBIO.L vs. ^GSPC - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
SBIO.L Invesco Nasdaq Biotech UCITS ETF	3.46%	32.89%	-2.00%	6.14%	-11.85%	-0.49%	27.35%	25.54%	-11.34%	21.45%
^GSPC S&P 500 Index	-3.95%	16.39%	23.31%	24.23%	-19.44%	26.89%	16.26%	28.88%	-6.24%	19.42%

Returns By Period

In the year-to-date period, SBIO.L achieves a 3.46% return, which is significantly higher than ^GSPC's -3.95% return. Over the past 10 years, SBIO.L has underperformed ^GSPC with an annualized return of 8.04%, while ^GSPC has yielded a comparatively higher 12.24% annualized return.

SBIO.L

• 1D: 2.44%
• 1M: -1.06%
• YTD: 3.46%
• 6M: 17.44%
• 1Y: 39.73%
• 3Y*: 13.23%
• 5Y*: 4.67%
• 10Y*: 8.04%

^GSPC

• 1D: 0.72%
• 1M: -4.45%
• YTD: -3.95%
• 6M: -2.02%
• 1Y: 16.73%
• 3Y*: 16.96%
• 5Y*: 10.34%
• 10Y*: 12.24%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

SBIO.L vs. ^GSPC — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SBIO.L

SBIO.L Risk / Return Rank: 86
SBIO.L Sharpe Ratio Rank: 85
SBIO.L Sortino Ratio Rank: 85
SBIO.L Omega Ratio Rank: 78
SBIO.L Calmar Ratio Rank: 90
SBIO.L Martin Ratio Rank: 93

^GSPC

^GSPC Risk / Return Rank: 67
^GSPC Sharpe Ratio Rank: 63
^GSPC Sortino Ratio Rank: 64
^GSPC Omega Ratio Rank: 69
^GSPC Calmar Ratio Rank: 60
^GSPC Martin Ratio Rank: 77

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

SBIO.L vs. ^GSPC - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Invesco Nasdaq Biotech UCITS ETF (SBIO.L) and S&P 500 Index (^GSPC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	SBIO.L	^GSPC	Difference
Sharpe ratio Return per unit of total volatility	1.77	0.92	+0.86
Sortino ratio Return per unit of downside risk	2.38	1.41	+0.97
Omega ratio Gain probability vs. loss probability	1.31	1.21	+0.10
Calmar ratio Return relative to maximum drawdown	3.21	1.41	+1.80
Martin ratio Return relative to average drawdown	14.30	6.61	+7.68
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

SBIO.L vs. ^GSPC - Sharpe Ratio Comparison

The current SBIO.L Sharpe Ratio is 1.77, which is higher than the ^GSPC Sharpe Ratio of 0.92. The chart below compares the historical Sharpe Ratios of SBIO.L and ^GSPC, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	SBIO.L	^GSPC	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.77	0.92	+0.86
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.22	0.61	-0.40
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.36	0.68	-0.32
Sharpe Ratio (All Time) Calculated using the full available price history	0.27	0.46	-0.19

Correlation

The correlation between SBIO.L and ^GSPC is 0.35, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Drawdowns

SBIO.L vs. ^GSPC - Drawdown Comparison

The maximum SBIO.L drawdown since its inception was -39.44%, smaller than the maximum ^GSPC drawdown of -56.78%. Use the drawdown chart below to compare losses from any high point for SBIO.L and ^GSPC.

Drawdown Indicators

	SBIO.L	^GSPC	Difference
Max Drawdown Largest peak-to-trough decline	-39.44%	-56.78%	+17.34%
Max Drawdown (1Y) Largest decline over 1 year	-14.07%	-12.14%	-1.93%
Max Drawdown (5Y) Largest decline over 5 years	-38.33%	-25.43%	-12.90%
Max Drawdown (10Y) Largest decline over 10 years	-38.33%	-33.92%	-4.41%
Current Drawdown Current decline from peak	-2.55%	-5.78%	+3.23%
Average Drawdown Average peak-to-trough decline	-17.03%	-10.75%	-6.28%
Ulcer Index Depth and duration of drawdowns from previous peaks	2.85%	2.60%	+0.25%

Volatility

SBIO.L vs. ^GSPC - Volatility Comparison

Invesco Nasdaq Biotech UCITS ETF (SBIO.L) has a higher volatility of 7.64% compared to S&P 500 Index (^GSPC) at 5.37%. This indicates that SBIO.L's price experiences larger fluctuations and is considered to be riskier than ^GSPC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	SBIO.L	^GSPC	Difference
Volatility (1M) Calculated over the trailing 1-month period	7.64%	5.37%	+2.27%
Volatility (6M) Calculated over the trailing 6-month period	14.10%	9.55%	+4.55%
Volatility (1Y) Calculated over the trailing 1-year period	22.31%	18.33%	+3.98%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	21.26%	16.90%	+4.36%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	22.28%	18.05%	+4.23%